In this video, health-care analyst David Williamson discusses Peregrine Pharmaceuticals' announcement and stock pop from completing enrollment of a phase 1 trial for its lead drug candidate bavituximab in breast cancer. Bavituximab has endured a lot of (clinical) trials and tribulations, including in NSCLC and pancreatic cancer, and this video puts today's news into perspective with the larger picture investors need to know.
